GENB — Generate Biomedicines Cashflow Statement
0.000.00%
Last trade - 00:00- $1.43bn
- $1.44bn
- $31.89m
Annual cashflow statement for Generate Biomedicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -181 | -223 |
| Depreciation | ||
| Non-Cash Items | 20.2 | 23.8 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | 28.1 | -14.6 |
| Change in Accounts Receivable | ||
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Other Liabilities | ||
| Cash from Operating Activities | -118 | -201 |
| Capital Expenditures | -3.45 | -3.51 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | -54.3 | 120 |
| Sale of Fixed Assets | ||
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | -57.7 | 117 |
| Financing Cash Flow Items | 5 | 13.2 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 91.3 | 28.1 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | -84.1 | -55.8 |